COMPLETED: Consortium on Targeting and Regeneration (HIRN-CTAR)

CTAR is investigating methods to increase or maintain functional beta cell mass in T1D through targeted manipulation of islet plasticity or engineered protection of beta cells from immune-mediated destruction.

Active: September 2014 – November 2023

 

Follow
×

Follow

us on our social networks.